Data from the 2014 Ebola virus outbreak at two Sierra Leone facilities reveal daily usage rates for disinfectant and personal protective equipment, informing future outbreaks.
A deep understanding of the Congo’s culture and time-honored public-health tactics are the keys to controlling the outbreak.
Relying on one potential vaccine from one company does not make sense, either in terms of ensuring resilient supply or the best protection against the virus.
It's unclear how many people the patients came into contact with in Mbandaka, a city of more than one million. The relatives who helped them leave the hospital may also be at risk.
Successful use of the vaccine requires response planners and vaccination teams to hit the right notes on several challenging communications messages, said the CEO of Gavi, the Vaccine Alliance, a public-private partnership that assists developing countries with immunization programs.
Health workers fighting Ebola in the Democratic Republic of Congo have run into an invisible but powerful hurdle - a belief system that deems the disease to be a curse or the result of evil spirits.
A standard randomized clinical trial doesn’t work when a pathogen circulates as rarely as Ebola does - researchers could vaccinate thousands of people and follow them for years without seeing any disease in the vaccine recipients or the control group.
The experimental treatment is made from an antibody isolated from the blood of a man who survived Ebola infection during the 1995 outbreak in the Congo.
The next two weeks will tell whether a vaccination campaign and public health measures can contain the Ebola outbreak in the Democratic Republic of Congo, according to a World Health Organization (WHO) official.
The grant will support the surge in activities of the DRC Government and international responders outlined under the approved three-month $56.8 million Ebola response plan, released by the DRC Government.